Novartis 4Q Revenues: $12.4 billion (+8%) 4Q Earnings: $1.1 billion (-5%) FY Revenues: $47.4 billion (+6%)   FY Earnings: $11.7 billion (-7%) Comments: Pharmaceuticals sales grew 12% to $6.2 billion in the quarter, driven by continued momentum of Entresto with sales of $518 million, up 63%, and Cosentyx with $965 million in sales, up 20%, and the launch uptake of Zolgensma with $186 million in sales. Oncology sales grew 7% driven by continued momentum on Kisqali with $155 mi...